Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".

Gobbini E, Langlais A, Missy P, Chanoine S, Besse B, Souquet PJ, Barlesi F, Audigier-Valette C, Métivier AC, Monnet I, Hureaux J, Jeannin G, Cadranel J, Lagrange A, Tran Q, Morin F, Molinier O, Westeel V, Girard N, Moro-Sibilot D.

Open source

DOI
10.1016/j.ejca.2025.115667
Published
2025-07-30
Container
Eur J Cancer
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.115667,
  title = {Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".},
  author = {Gobbini E and  Langlais A and  Missy P and  Chanoine S and  Besse B and  Souquet PJ and  Barlesi F and  Audigier-Valette C and  Métivier AC and  Monnet I and  Hureaux J and  Jeannin G and  Cadranel J and  Lagrange A and  Tran Q and  Morin F and  Molinier O and  Westeel V and  Girard N and  Moro-Sibilot D.},
  year = {2025},
  journal = {Eur J Cancer},
  doi = {10.1016/j.ejca.2025.115667},
  url = {https://doi.org/10.1016/j.ejca.2025.115667}
}

RIS

TY  - JOUR
TI  - Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".
AU  - Gobbini E
AU  -  Langlais A
AU  -  Missy P
AU  -  Chanoine S
AU  -  Besse B
AU  -  Souquet PJ
AU  -  Barlesi F
AU  -  Audigier-Valette C
AU  -  Métivier AC
AU  -  Monnet I
AU  -  Hureaux J
AU  -  Jeannin G
AU  -  Cadranel J
AU  -  Lagrange A
AU  -  Tran Q
AU  -  Morin F
AU  -  Molinier O
AU  -  Westeel V
AU  -  Girard N
AU  -  Moro-Sibilot D.
PY  - 2025
JO  - Eur J Cancer
DO  - 10.1016/j.ejca.2025.115667
UR  - https://doi.org/10.1016/j.ejca.2025.115667
ER  - 

APA

E, G., A, L., P, M., S, C., B, B., PJ, S., F, B., C, A., AC, M., I, M., J, H., G, J., J, C., A, L., Q, T., F, M., O, M., V, W., N, G., & D., M. (2025). Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".. Eur J Cancer. https://doi.org/10.1016/j.ejca.2025.115667

Source records